Dupixent (dupilumab) is one of the highest-revenue drugs in the world, approved for multiple type 2 inflammatory conditions including atopic dermatitis, asthma, and eosinophilic esophagitis. Despite its efficacy, post-market surveillance has identified a cluster of serious adverse events: ocular surface disease (conjunctivitis, keratitis, limbal stem cell deficiency, corneal damage), paradoxical eosinophilia, and in some patients worsening EoE. Failure-to-warn litigation is developing as plaintiff attorneys evaluate FAERS data and published case series.
IL-4/IL-13 blockade disrupts goblet cell function in the conjunctiva, causing ocular surface disease. Paradoxical eosinophilia: blocking certain pathways may redirect eosinophils to tissues, worsening inflammatory conditions. Published case series in peer-reviewed journals document both mechanisms. FDA label updates acknowledging these events support knowledge-based failure-to-warn claims.
Dupixent (dupilumab) is an IL-4/IL-13 blocker approved for atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis (EoE). Post-market adverse event reports and case studies have flagged paradoxical eosinophilic conditions, severe ocular side effects (conjunctivitis, limbal stem cell deficiency, corneal damage), and in some patients, worsening of EoE — the very condition it treats. Failure-to-warn litigation is in early formation.